Hypothesis

Clearing senescent cells with senolytics restores circadian amplitude and phase coherence by reducing SASP-driven CD38 activity, thereby increasing NAD+ levels and SIRT1-mediated deacetylation of BMAL1/CLOCK complexes.

Mechanistic Rationale

Senescent cells secrete a proinflammatory milieu (SASP) that includes IL-6 and PAI-1, which upregulate CD38 expression on neighboring cells[4]. CD38 hydrolyzes NAD+, lowering the pool available for SIRT1 deacetylase activity. SIRT1 directly deacetylates BMAL1, promoting its transcriptional activity and stabilizing the core clock feedback loop[1]. When NAD+ declines, SIRT1 activity falls, leading to hyperacetylated BMAL1, reduced DNA repair capacity, and weakened circadian oscillations[2]. Senolytic removal of senescent cells diminishes SASP, decreasing CD38 expression and preserving NAD+. The resulting NAD+ surplus reactivates SIRT1, which then deacetylates BMAL1, enhancing its binding to E-box elements and driving robust transcription of Per, Cry, and clock-controlled genes. This creates a positive feedback loop where improved clock function further limits senescence by boosting DNA repair and antioxidative defenses.

Experimental Design

Model: 20‑month‑old C57BL/6J mice treated with the senolytic combination dasatinib + quercetin (D+Q) or vehicle control for 12 weeks (n=15 per group). Readouts:

• In vivo circadian monitoring: wheel‑running activity and core body temperature telemetry to assess period, amplitude, and phase stability.
• Ex vivo bioluminescence: PER2::LUC reporter rhythms harvested from suprachiasmatic nucleus (SCN) and liver explants.
• Biochemical assays: NAD+ quantification via LC‑MS, CD38 mRNA/protein (qPCR, Western blot), SIRT1 activity (fluorometric deacetylase assay), BMAL1 acetylation status (immunoprecipitation followed by anti‑acetyl‑lysine Western).
• Senescence burden: p16^Ink4a^ and SA‑β‑gal staining in liver, adipose, and kidney. Intervention arms: (1) D+Q, (2) D+Q + SIRT1 inhibitor EX527, (3) vehicle, (4) vehicle + EX527. This isolates whether SIRT1 activity is necessary for any circadian rescue.

Expected Outcomes

If the hypothesis holds, D+Q‑treated mice will show:

• Significant increase in NAD+ levels (~30‑40% rise) and SIRT1 activity relative to vehicle.
• Reduced CD38 expression in peripheral tissues.
• Decreased BMAL1 acetylation and enhanced DNA repair marker (γH2AX) clearance.
• Restored wheel‑running amplitude (≥25% increase) and tighter period distribution compared with aged controls.
• Ex vivo PER2::LUC rhythms from SCN and liver will exhibit higher amplitude and faster damping reversal. Crucially, co‑administration of EX527 will abolish the circadian improvements despite senolytic treatment, confirming SIRT1 dependence.

Potential Pitfalls and Alternatives

Compensatory NAD+ salvage pathways (e.g., NAMPT upregulation) might mask CD38 effects; measuring NAMPT activity will clarify contributions. SASP heterogeneity could mean that senolytic regimens do not uniformly reduce CD38‑inducing factors; profiling SASP cytokines post‑treatment will refine the model. If circadian rescue occurs without NAD+ changes, alternative mechanisms such as microglial modulation or extracellular vesicle miRNA transfer (as suggested by altered EV cargo after senolysis[6]) should be explored.

This hypothesis directly links senocyte clearance to NAD+‑SIRT1 clock regulation, offering a testable biomarker (NAD+/SIRT1 activity) for senolytic efficacy and positioning circadian restoration as a measurable hallmark of youthful systems integrity.